Comparison of Gd-BOPTA and Gd-DOTA for Peripheral CE-MRA

Lohr, Hendrik A.; Froehlich, Johannes M.; Pfyffer, Markus; Bader, Christoph W.; Zollikofer, Christoph L.; Wentz, K. U.

doi:10.1016/s1076-6332(03)80250-7

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the first and only agent that received FDA approval, gadofosveset, is no longer in production in the US due to small market niche. The commonly available gadobenate dimeglumine (MultiHance) demonstrates weak albumin binding and mildly increased vascular persistence (21), although the practical benefit of this subtle difference remains to be debated. Ferumoxytol, a non-gadolinium superparamagnetic iron oxide contrast agent, demonstrates a prolonged vascular residence time (22) and is a promising vascular imaging agent especially in patient with a contraindication to gadolinium such as renal failure (23).…”

Section: Contrast Enhanced (Ce) Mramentioning

confidence: 99%

Vascular magnetic resonance angiography techniques

Kuo¹,

Nagpal²,

Ghoshhajra³

et al. 2019

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

Magnetic resonance angiography (MRA) denotes a unique option for the evaluation of peripheral vasculature due to its noninvasive nature, lack of ionizing radiation exposure, potential for non-contrast examination, and ability for generating volumetric representations that showcase vascular pathology. The constant evolution of the available MRA techniques, however, makes understanding and determining an optimal imaging protocol difficult. Here we present a brief overview of the major MRA sequence options, their major weaknesses and strengths, and related imaging considerations. Understanding the technical underpinnings of the various MRA methods helps with recognition of common imaging issues and artifacts and rendering clinically relevant interpretations.

show abstract

Section: Contrast Enhanced (Ce) Mramentioning

confidence: 99%